Publications by authors named "T Heurtaux"

Loss-of-function mutations in PARK7, encoding for DJ-1, can lead to early onset Parkinson's disease (PD). In mice, Park7 deletion leads to dopaminergic deficits during aging, and increased sensitivity to oxidative stress. However, the severity of the reported phenotypes varies.

View Article and Find Full Text PDF
Article Synopsis
  • Gliomas, particularly glioblastoma multiforme (GBM), are the most prevalent malignant brain tumors with a median survival of just 15 months due to resistance to treatment.
  • Current treatments include surgery, radiotherapy, and chemotherapy, and so far, only 12 anti-brain tumor chemotherapies have been approved, primarily alkylating agents.
  • Researchers used subtype-specific metabolic models to simulate and predict effective drugs and combinations for gliomas, identifying 33 potential single drugs and 17 combinations, some of which could improve survival rates compared to existing treatments.
View Article and Find Full Text PDF

Alzheimer's disease (AD) progression and pathology show pronounced sex differences, but the factors driving these remain poorly understood. To gain insights into early AD-associated molecular changes and their sex dependency for tau pathology in the cortex, we performed single-cell RNA-seq in the THY-Tau22 AD mouse model. By examining cell type-specific and cell type-agnostic AD-related gene activity changes and their sex-dimorphism for individual genes, pathways and cellular sub-networks, we identified both statistically significant alterations and interpreted the upstream mechanisms controlling them.

View Article and Find Full Text PDF

Parkinson's disease (PD) is a neurological disorder characterized by motor dysfunction, dopaminergic neuron loss, and alpha-synuclein (αSyn) inclusions. Many PD risk factors are known, but those affecting disease progression are not. Lifestyle and microbial dysbiosis are candidates in this context.

View Article and Find Full Text PDF

Brain disorders represent 32% of the global disease burden, with 169 million Europeans affected. Constraint-based metabolic modelling and other approaches have been applied to predict new treatments for these and other diseases. Many recent studies focused on enhancing, among others, drug predictions by generating generic metabolic models of brain cells and on the contextualisation of the genome-scale metabolic models with expression data.

View Article and Find Full Text PDF